Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 1.0 | - |
Min SIP Amount | ₹200 | - |
Expense Ratio | 2.45 | - |
NAV | ₹28.53 | - |
Fund Started | 08 Feb 2019 | - |
Fund Size | ₹84.19 Cr | - |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 16.12% | - |
3 Year | 20.87% | - |
5 Year | 16.76% | - |
1 Year
3 Year
5 Year
Equity | 96.62% | - |
Cash | 3.38% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.73% |
Cipla Ltd. | 5.43% |
Torrent Pharmaceuticals Ltd. | 4.95% |
Divi's Laboratories Ltd. | 4.84% |
Aurobindo Pharma Ltd. | 4.27% |
Piramal Pharma Ltd. | 4.22% |
Neuland Laboratories Ltd. | 4.11% |
Fortis Healthcare Ltd. | 4.00% |
Alkem Laboratories Ltd. | 3.76% |
Artemis Medicare Services Ltd. | 3.61% |
Name | Karan Doshi | - |
Start Date | 31 Jul 2023 | - |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | - |
Launch Date | 08 Feb 2019 | - |
Description
Launch Date